 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- LCB84 / J&J
Preclinical evaluation of LCB84, a novel next-generation TROP2 directed ADC utilizing a cancer selective linker and an MMAE payload (Section 22) - Mar 5, 2024 - Abstract #AACR2024AACR_7994;
Additionally, LCB84 shows a stable preclinical pharmacokinetic profile with minimal loss of payload over time. The utilization of an ADC for target-mediated delivery, in combination with a stable beta-glucuronide trigger for selective payload release in tumors, allows for a superior preclinical therapeutic index which is expected to translate to a best-in-class ADC in the clinic.
- |||| LCB84 / J&J
Enrollment open, Combination therapy, Metastases: A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors (clinicaltrials.gov) - Oct 16, 2023
P1/2, N=300, Recruiting, Sponsor: LegoChem Biosciences, Inc
The utilization of an ADC for target-mediated delivery, in combination with a stable beta-glucuronide trigger for selective payload release in tumors, allows for a superior preclinical therapeutic index which is expected to translate to a best-in-class ADC in the clinic. Not yet recruiting --> Recruiting
- LCB84 / LegoChem Biosci
LCB84: A Next-Gen TROP2 Targeting ADC Utilizing LegoChem Biosciences' Tumor Selective Linker () - Aug 9, 2023 - Abstract #ADCUSA2023ADC_USA_93;
Not yet recruiting --> Recruiting Sponsored by LCB LEGOCHEMBIO
- ||||| LCB84 / J&J
New P1/2 trial, Combination therapy, Metastases: A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors (clinicaltrials.gov) - Jul 12, 2023
P1/2, N=300, Not yet recruiting, Sponsor: LegoChem Biosciences, Inc